ZYME (Zymeworks) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 04, 2026)


ZYME Zymeworks Inc ZYME
66 GF Score
Price $26.31
GF Value $24.21
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zymeworks Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Zymeworks's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

ZYME vs SRPT, BCAX, INVA: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Zymeworks's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Zymeworks's Margin of Safety % (DCF Dividends Based) falls into.


ZYME
66GF Score
Zymeworks Inc ZYME
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $26.31 is trading 8.7% above its estimated GF Value™ of $24.21. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $24.21 vs. price of $26.31 (8.7% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for ZYME

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.31
Price
$24.21
GF Value